Female Urethral Slings Market to Reach US$ 4.20 Bn by 2027

Request a PDF Sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=60162

High Prevalence of Urinary Incontinence and Overactive Bladder to Propel Market

Urinary incontinence is one of the highly prevalent and largely underreported and underdiagnosed urological disorders across the globe. It affects millions of people and has severe impact on physical, psychological, as well as emotional health. Twice as many women as men are affected by this condition and its incidence increases with age. Several factors such as weak pelvic floor muscles, urethral sphincters, obesity, pregnancy & childbirth, urinary tract infection, and neurological disorders cause urinary incontinence. An estimated 200 million people globally are affected by some form of urinary incontinence or bladder problems. Stress urinary incontinence is the most common form affecting millions of people. Various studies have suggested that 24% to 45% of women aged above 30 suffer from stress urinary incontinence. Large patient pool with stress urinary incontinence and overactive bladder symptoms is projected to fuel the growth of the global urinary incontinence treatment devices during the forecast period.

Electrical Stimulation Devices to be Most Attractive Segment

The report offers detailed segmentation of the global urinary incontinence treatment devices market based on product, incontinence type, and end-user. In terms of product, the electrical stimulation devices segment is poised to account for leading share of the global market during the forecast period. Factors attributed to the higher share of the segment include rise in demand for minimally invasive/wearable and non-implantable electrical stimulation devices to strengthen the pelvic floor muscles, high success rates with electrical stimulation devices, and favorable medical reimbursement policies in developed countries for implantable electrical stimulation devices. Development and launch of new electrical stimulation devices for percutaneous tibial nerve stimulation for the treatment of overactive bladder (such as Medtronic plc’s NURO System) is projected to drive the segment during the forecast period. Moreover, recent launch of wearable electrical stimulation device, INNOVO, by Atlantic Therapeutics and rise in demand for InControl Medical’s FDA-approved over-the-counter electrical stimulation device are expected to propel the segment during the forecast period.

Urge Urinary Incontinence Segment to Dominate Market

In terms of incontinence type, the urge urinary incontinence segment is projected to dominate the global urinary incontinence treatment market during the forecast period. The segment is anticipated to expand at a high CAGR from 2019 to 2027. Millions of people across the globe are affected by overactive bladder which leads to urge urinary incontinence. Dominance of the segment is attributed to higher cost of treatment devices, especially implantable electrical stimulation devices, than other treatment devices/methods. Therefore, increase in incidence of urge urinary incontinence, rise in adoption of electrical stimulation devices for overactive bladder treatment, and new product launches are expected to contribute to the growth of the segment during the forecast period.

Hospitals Segment to Lead Market

Based on end-user, the hospitals segment is projected to account for major share of the global urinary incontinence treatment devices market from 2019 to 2027. The segment is anticipated to expand at a high CAGR from 2019 to 2027. Ambulatory surgery centers is expected to be the second leading segment in terms of market share during the forecast period. High share of the segment is attributed to increase in the number of surgical procedures for the treatment of all types of urinary incontinence and favorable reimbursement policies for medical devices in most of the developed and developing countries. The home use segment is likely to grow at a rapid pace from 2019 to 2027. Availability and high adoption of over-the-counter electrical stimulation and non-invasive treatment devices for the effective management of urinary incontinence are the key factors driving the home use segment.

Europe to Create High Incremental Opportunity

In terms of revenue, North America is projected to dominate the global urinary incontinence treatment devices market from 2019 to 2027. This is attributed to early adoption of technologies, large patient pool of urinary incontinence, and easy availability & lucrative medical reimbursement policies in the U.S. and Canada. Europe is anticipated to be the second largest and most attractive market for urinary incontinence treatment devices. The market in the region is expected to expand at a high CAGR during the forecast period due to high prevalence and increase in incidence of urinary incontinence, surge in adoption of technologically advanced products, large base of medical devices companies, and large number of products in the pipeline for the treatment of urinary incontinence. The market in the U.K. is likely to expand at the highest CAGR during the forecast period. The country is projected to gain market share from 2019 to 2027. An estimated 15,000 mid-urethral sling surgical procedures (MUS) in women are performed in the U.K. each year. Moreover, high incidence of post radical prostatectomy urinary incontinence in men is anticipated to accelerate the growth of the market in the country during the forecast period. Asia Pacific is expected to be the second fastest growing market for urinary incontinence treatment devices owing to large population in countries such as India and China, large geriatric population in Japan, and improving health care facilities.

New Product Development and Launch in International Market: Key Trend among Leading Players

The report also provides profiles of leading players operating in the global urinary incontinence treatment devices market. Boston Scientific Corporation, C. R. Bard, Inc. (Becton, Dickinson and Company), Coloplast Group, Promedon Group, Medtronic plc, and Ethicon US, LLC. (Johnson & Johnson) are the major players operating in the market offering products with proprietary technologies. Several companies have introduced mini slings for minimally invasive placement of mid-urethral slings with polypropylene sling material. In March 2016, Medtronic plc launched the NURO System, a percutaneous tibial neuromodulation device for the treatment of overactive bladder. The NURO System is the second product in the market after Cogentix Medical’s Urgent PC that targets tibial nerve for pelvic floor strengthening. Other prominent players in the global urinary incontinence treatment devices market include ZSI Surgical Implants S.R.L., InControl Medical LLC, Hollister Incorporated, Atlantic Therapeutics Group Ltd., B. Braun Melsungen AG, A.M.I. GmbH, and Teleflex Incorporated